vs
Side-by-side financial comparison of Honest Company, Inc. (HNST) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $88.0M, roughly 1.1× Honest Company, Inc.). Vericel Corp runs the higher net margin — 25.0% vs -26.8%, a 51.8% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -11.8%). Honest Company, Inc. produced more free cash flow last quarter ($18.1M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 1.0%).
The Honest Company, Inc. is an American digital-first consumer goods company, based in Los Angeles and founded by actress Jessica Alba, Christopher Gavigan, and Brian Lee. The company had $319 million in 2021 sales, and was valued at roughly $550 million as of February 2022. Carla Vernón, Chief Executive Officer, is one of the first Afro-Latina CEOs of a U.S. publicly traded company. The Honest Company has raised multiple rounds of venture capital, and went public via an initial public offeri...
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
HNST vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $88.0M | $92.9M |
| Net Profit | $-23.6M | $23.2M |
| Gross Margin | 15.7% | 78.7% |
| Operating Margin | -27.5% | 24.1% |
| Net Margin | -26.8% | 25.0% |
| Revenue YoY | -11.8% | 23.3% |
| Net Profit YoY | -2813.2% | 17.3% |
| EPS (diluted) | $-0.21 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $88.0M | $92.9M | ||
| Q3 25 | $92.6M | $67.5M | ||
| Q2 25 | $93.5M | $63.2M | ||
| Q1 25 | $97.3M | $52.6M | ||
| Q4 24 | $99.8M | $75.4M | ||
| Q3 24 | $99.2M | $57.9M | ||
| Q2 24 | $93.0M | $52.7M | ||
| Q1 24 | $86.2M | $51.3M |
| Q4 25 | $-23.6M | $23.2M | ||
| Q3 25 | $758.0K | $5.1M | ||
| Q2 25 | $3.9M | $-553.0K | ||
| Q1 25 | $3.3M | $-11.2M | ||
| Q4 24 | $-809.0K | $19.8M | ||
| Q3 24 | $165.0K | $-901.0K | ||
| Q2 24 | $-4.1M | $-4.7M | ||
| Q1 24 | $-1.4M | $-3.9M |
| Q4 25 | 15.7% | 78.7% | ||
| Q3 25 | 37.3% | 73.5% | ||
| Q2 25 | 40.4% | 73.7% | ||
| Q1 25 | 38.7% | 69.0% | ||
| Q4 24 | 38.8% | 77.6% | ||
| Q3 24 | 38.7% | 71.9% | ||
| Q2 24 | 38.3% | 69.5% | ||
| Q1 24 | 37.0% | 68.9% |
| Q4 25 | -27.5% | 24.1% | ||
| Q3 25 | 0.3% | 5.1% | ||
| Q2 25 | 3.1% | -3.2% | ||
| Q1 25 | 2.6% | -24.3% | ||
| Q4 24 | -1.0% | 24.5% | ||
| Q3 24 | 0.1% | -4.3% | ||
| Q2 24 | -4.3% | -11.5% | ||
| Q1 24 | -1.5% | -10.7% |
| Q4 25 | -26.8% | 25.0% | ||
| Q3 25 | 0.8% | 7.5% | ||
| Q2 25 | 4.1% | -0.9% | ||
| Q1 25 | 3.3% | -21.4% | ||
| Q4 24 | -0.8% | 26.3% | ||
| Q3 24 | 0.2% | -1.6% | ||
| Q2 24 | -4.4% | -8.9% | ||
| Q1 24 | -1.6% | -7.5% |
| Q4 25 | $-0.21 | $0.46 | ||
| Q3 25 | $0.01 | $0.10 | ||
| Q2 25 | $0.03 | $-0.01 | ||
| Q1 25 | $0.03 | $-0.23 | ||
| Q4 24 | $-0.01 | $0.40 | ||
| Q3 24 | $0.00 | $-0.02 | ||
| Q2 24 | $-0.04 | $-0.10 | ||
| Q1 24 | $-0.01 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.6M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $169.7M | $354.6M |
| Total Assets | $225.4M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.6M | $137.5M | ||
| Q3 25 | $71.5M | $135.4M | ||
| Q2 25 | $72.1M | $116.9M | ||
| Q1 25 | $72.8M | $112.9M | ||
| Q4 24 | $75.4M | $116.2M | ||
| Q3 24 | $53.4M | $101.7M | ||
| Q2 24 | $36.6M | $102.5M | ||
| Q1 24 | $33.6M | $110.6M |
| Q4 25 | $169.7M | $354.6M | ||
| Q3 25 | $190.2M | $321.9M | ||
| Q2 25 | $187.0M | $306.8M | ||
| Q1 25 | $180.4M | $295.5M | ||
| Q4 24 | $174.3M | $292.0M | ||
| Q3 24 | $133.9M | $257.5M | ||
| Q2 24 | $129.7M | $243.0M | ||
| Q1 24 | $124.8M | $233.9M |
| Q4 25 | $225.4M | $488.0M | ||
| Q3 25 | $241.5M | $453.3M | ||
| Q2 25 | $249.0M | $435.6M | ||
| Q1 25 | $265.3M | $424.6M | ||
| Q4 24 | $247.4M | $432.7M | ||
| Q3 24 | $209.2M | $390.4M | ||
| Q2 24 | $200.2M | $376.8M | ||
| Q1 24 | $198.1M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.3M | $15.0M |
| Free Cash FlowOCF − Capex | $18.1M | $12.8M |
| FCF MarginFCF / Revenue | 20.5% | 13.8% |
| Capex IntensityCapex / Revenue | 1.4% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $13.6M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.3M | $15.0M | ||
| Q3 25 | $-504.0K | $22.1M | ||
| Q2 25 | $-745.0K | $8.2M | ||
| Q1 25 | $-2.9M | $6.6M | ||
| Q4 24 | $-16.8M | $22.2M | ||
| Q3 24 | $15.1M | $10.2M | ||
| Q2 24 | $2.9M | $18.5M | ||
| Q1 24 | $336.0K | $7.2M |
| Q4 25 | $18.1M | $12.8M | ||
| Q3 25 | $-624.0K | $19.5M | ||
| Q2 25 | $-826.0K | $81.0K | ||
| Q1 25 | $-3.0M | $-7.6M | ||
| Q4 24 | $-17.2M | $8.5M | ||
| Q3 24 | $15.0M | $-9.2M | ||
| Q2 24 | $2.9M | $1.8M | ||
| Q1 24 | $260.0K | $-6.8M |
| Q4 25 | 20.5% | 13.8% | ||
| Q3 25 | -0.7% | 28.8% | ||
| Q2 25 | -0.9% | 0.1% | ||
| Q1 25 | -3.1% | -14.5% | ||
| Q4 24 | -17.2% | 11.2% | ||
| Q3 24 | 15.1% | -15.9% | ||
| Q2 24 | 3.1% | 3.4% | ||
| Q1 24 | 0.3% | -13.3% |
| Q4 25 | 1.4% | 2.4% | ||
| Q3 25 | 0.1% | 3.9% | ||
| Q2 25 | 0.1% | 12.9% | ||
| Q1 25 | 0.1% | 27.0% | ||
| Q4 24 | 0.3% | 18.3% | ||
| Q3 24 | 0.1% | 33.5% | ||
| Q2 24 | 0.0% | 31.8% | ||
| Q1 24 | 0.1% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | -0.66× | 4.35× | ||
| Q2 25 | -0.19× | — | ||
| Q1 25 | -0.90× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 91.42× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HNST
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
